Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20767279 | 0.88 | ARF6 (0.74) | ARF6PLAT | |
| SCHEMBL20767271 | 0.79 | ARF6 (1.00) | ARF6 | |
| SCHEMBL22902196 | 0.76 | ARF6 (1.00) | ARF6 | |
| SCHEMBL20796208 | 0.75 | ARF6 (0.82) | ARF6 | |
| SCHEMBL20796201 | 0.75 | ARF6 (1.00) | ARF6PLAT | |
| SCHEMBL20796209 | 0.74 | ARF6 (0.81) | ARF6PLAT | |
| SCHEMBL20796512 | 0.72 | ARF6 (0.81) | ARF6 | |
| SCHEMBL20796517 | 0.71 | ARF6 (1.00) | ARF6PLAT | |
| SCHEMBL20796514 | 0.71 | ARF6 (0.83) | ARF6 | |
| SCHEMBL20796487 | 0.70 | ARF6 (1.00) | ARF6PLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414442-B2 | ARF6 inhibitors and related methods | NAVIGEN, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. | 2021-01-21 | — | — | US | disclosed |
| EP-3672597-A2 | ARF6 INHIBITORS AND RELATED METHODS | Navigen, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| WO-2019040499-A2 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040499-A2 | ARF6 INHIBITORS AND RELATED METHODS | NAVIGEN, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017201-A1 | ARF6 INHIBITORS AND RELATED METHODS | ARF6, ARF1, ARF5 | ARF6 1/4885PLAT 621/4885 |
| US-11414442-B2 | ARF6 inhibitors and related methods | ARF6, ARF1, ARF5 | ARF6 1/4885PLAT 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.